ÂÜÀòÂÒÂ×

Barbara Fox is an accomplished biopharma executive with extensive experience in leadership roles across multiple companies. Currently serving as Interim CEO and Independent Board Member at Alphina Therapeutics since March 2024, Barbara also serves as an Independent Board Member for BioHybrid Solutions and Diagonal Therapeutics. Previously, as Chief Executive Officer at Rheos Medicines, Barbara led the development of novel medicines targeting immune cell metabolism, while at Tilos Therapeutics, Barbara was the founding CEO who successfully sold the company to Merck for $773M. Barbara founded Avaxia Biologics, securing significant equity financing, and earlier established Recovery Pharmaceuticals to develop treatments for addiction. Educational credentials include a PhD in Chemistry from the Massachusetts Institute of Technology and an AB in Chemistry from Bryn Mawr College.